Literature DB >> 11396100

Rheumatoid arthritis. Treatment of early disease.

M Boers1.   

Abstract

Treatment of rheumatoid arthritis (RA) is changing with the rapid increase of information on the efficacy of old and new antirheumatic agents. This article provides an opinionated review of the data currently available and makes a case for rapid and aggressive treatment of all patients with RA as early as possible. In the future, corticosteroids will be an important component of such treatment strategies.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11396100     DOI： 10.1016/s0889-857x(05)70209-x

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  12 in total

1.  Diastolic dysfunction in rheumatoid arthritis and duration of disease.

Authors:  Irfan Yavasoglu; Taskin Senturk; Alper Onbasili
Journal:  Rheumatol Int       Date:  2008-05-22       Impact factor: 2.631

Review 2.  Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Amy S Mudano; Elizabeth Tanjong Ghogomu; Maria E Suarez-Almazor; Rachelle Buchbinder; Lara J Maxwell; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 3.  Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Ahmed Kotb; Robin Christensen; Amy S Mudano; Lara J Maxwell; Nipam P Shah; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2016-05-13

4.  Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice.

Authors:  Kenji Yumoto; Muneaki Ishijima; Susan R Rittling; Kunikazu Tsuji; Yoko Tsuchiya; Shigeyuki Kon; Akira Nifuji; Toshimitsu Uede; David T Denhardt; Masaki Noda
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

Review 5.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Vokko P van Halm; Ben A C Dijkmans
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Amy S Mudano; Lara J Maxwell; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Maria E Suarez-Almazor; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

8.  Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).

Authors:  A Kastbom; G Strandberg; A Lindroos; T Skogh
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

9.  Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis.

Authors:  Jiamu Du; Sheng Hou; Chen Zhong; Zheng Lai; Hui Yang; Jianxin Dai; Dapeng Zhang; Hao Wang; Yajun Guo; Jianping Ding
Journal:  J Mol Biol       Date:  2008-07-31       Impact factor: 5.469

Review 10.  Atherogenic lipid profiles and its management in patients with rheumatoid arthritis.

Authors:  Michael T Nurmohamed
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.